Hypotheses
499 hypotheses · 178 with trials running
Showing 21 items
Protect nerves
secondary progressive MSPromisingPhase 32 trials · 1 running · Thioctic acid
Slow progression
primary progressive MSMixedPhase 32 trials · 0 running · Biotin
Slow progression
secondary progressive MSMixedPhase 32 trials · 0 running · Biotin
Repair myelin
relapsing MSResults pendingPhase 21 trial · 0 running · Metformin
Slow progression
primary progressive MSBeing testedPhase 32 trials · 2 running · Metformin
Slow progression
secondary progressive MSBeing testedPhase 32 trials · 2 running · Metformin
Protect nerves
primary progressive MSBeing testedPhase 21 trial · 1 running · Acetylcysteine
Protect nerves
secondary progressive MSBeing testedPhase 21 trial · 1 running · Acetylcysteine
Protect nerves
primary progressive MSBeing testedPhase 31 trial · 1 running ·
Protect nerves
secondary progressive MSBeing testedPhase 31 trial · 1 running ·
Protect nerves
primary progressive MSBeing testedPhase 31 trial · 1 running ·
Stop relapses
relapsing and progressive MSBeing tested1 trial · 1 running · Acetylcysteine
Stop relapses
MS (type not specified)Being testedPhase 21 trial · 1 running · Metformin
Slow progression
primary progressive MSFailed in phase 2Phase 32 trials · 1 running · Thioctic acid
Slow progression
secondary progressive MSFailed in phase 2Phase 32 trials · 1 running · Thioctic acid
Protect nerves
relapsing MSNo clear answer1 trial · 0 running ·
Protect nerves
relapsing MSNo clear answerPhase 21 trial · 0 running · Metformin
Protect nerves
optic neuritisNo clear answerPhase 11 trial · 0 running · Thioctic acid
Stop relapses
primary progressive MSNo clear answerPhase early 11 trial · 0 running · Metformin
Stop relapses
secondary progressive MSNo clear answerPhase early 11 trial · 0 running · Metformin
Stop relapses
secondary progressive MSNo clear answerPhase 2/31 trial · 0 running · Thioctic acid
How a status is decided
A hypothesis is Confirmed when two or more controlled phase 3 trials met their main goal, or when one did and a medicine of the same approach is approved in the EU or the US for that use. With one positive phase 3 trial and no approval it is Supported by one trial. Analyses that only compare an active comparator with placebo, such as interferon beta against placebo inside a laquinimod trial, do not count as the tested medicine’s result.
- Confirmed
- Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Supported by one trial
- One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.
- Promising
- Worked in a controlled phase 2 trial. A signal, not proof.
- Mixed
- Controlled trials disagree.
- Results pending
- Trials finished, but not all results are read yet.
- Being tested
- Trials are running now. No verdict yet.
- Failed in phase 2
- Controlled phase 2 trials did not meet their main goal for this group.
- Failed in phase 3
- Controlled phase 3 trials did not meet their main goal for this group. This does not rule out the mechanism in other groups or with other medicines.
- No clear answer
- Tried, but no controlled phase 2 or 3 result yet.
- Not yet tested
- Proposed or suggested by genetics. Not yet tested in MS.
Unread results can leave a status pending. Two or more phase 3 trials that met their goal, with none against, give a verdict even when an extension study at the same phase has no readable result.
“Failed in phase 3” applies to the patient group shown. A hypothesis can fail in primary progressive MS and work in relapsing MS.
Not yet tested items come from two places: proposed hypotheses, and genes linked to MS by human genetics that existing medicines act on but that have never been tried in MS.
Nothing here is linked or edited by hand. To report an error, use the contact form; we fix the rule, so the fix applies everywhere.